Brand Intelligence Graph
Company Overview
About Unity Biotechnology
Unity Biotechnology is the most clinically advanced senolytic drug company, with its UBX1325 program delivering long-lasting vision improvements in diabetic macular edema (DME) from a single intravitreal senolytic injection. The 48-week Phase 2 BEHOLD trial data published in NEJM Evidence (one of the highest-impact medical journals) confirmed durable efficacy — maintained vision improvement with a single injection over nearly a year — validating the senolytic hypothesis in human ocular disease.
Business Model & Competitive Advantage
UBX1325 is a BCL-xL inhibitor that selectively induces apoptosis in senescent microvascular endothelial cells in the diabetic retina, which are thought to drive DME through SASP-mediated vascular permeability and inflammatory signaling. A single injection clears these senescent cells and the inflammatory environment they create, allowing the remaining healthy cells to restore vascular function. The NEJM Evidence publication provides the academic credibility needed to inform Phase 3 trial design.
Competitive Landscape 2025–2026
Unity is a bellwether for the senolytic field: its eye programs have provided the first controlled human evidence that removing senescent cells has durable therapeutic benefit, establishing the biological basis that the broader senolytic category depends on. Phase 3 design decisions being made in 2026 will determine whether UBX1325 advances toward regulatory approval and market launch — which would be the first FDA-approved senolytic drug in history.
Key Differentiators
Emerging Innovator
Unity Biotechnology is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Unity Biotechnology with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Unity Biotechnology? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Unity Biotechnology Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Unity Biotechnology vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →